VRDN Stock — Viridian Therapeutics Inc.: Cash, EV, Pipeline

Share price

$22.00

Market cap

$2,492.4M

Cash

$981.5M

Enterprise value

$1,531.8M

Balance sheet

Cash	$981.5M
Debt	$20.9M
Net cash	$960.6M
Enterprise value	$1,531.8M
Basic shares	113.2M shares
Fully diluted shares	148.2M shares
Fully diluted market cap	$3,260.2M
Cash per share	$8.67

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading VRDN daily closes…

Loading price history…

Pipeline assets

Veligrotug

Phase 3 · Active Modality: monoclonal antibody

Target IGF-1R

Partnerships Kissei Pharmaceutical: exclusive license to develop and commercialize veligrotug and elegrobart in Japan

Indications

Thyroid eye disease (TED) (Phase 3)

Status note Differentiated humanized anti-IGF-1R monoclonal antibody for intravenous administration in TED. FDA granted Breakthrough Therapy designation; the company's most advanced program, now seeking marketing approval.

Elegrobart

Phase 3 · Active Modality: monoclonal antibody

Aliases VRDN-003

Target IGF-1R

Partnerships Kissei Pharmaceutical: exclusive license to develop and commercialize veligrotug and elegrobart in Japan; Zenas BioPharma: license for IGF-1R antibody products for non-oncology indications in greater China

Indications

Active TED (Phase 3)
Chronic TED (Phase 3)

Status note Anti-IGF-1R monoclonal antibody for subcutaneous administration in TED. Evaluating in two global Phase 3 trials, REVEAL-1 (active TED) and REVEAL-2 (chronic TED); conducting a safety study to meet the 300-patient safety database requirement.

Anti-TSHR candidate (unnamed)

Preclinical · Active Modality: monoclonal antibody

Target TSHR

Partnerships Paragon Therapeutics: option/research agreement covering antibody technology

Indications

Graves' disease (Preclinical)
Thyroid eye disease (TED) (Preclinical)

Status note Anti-TSHR candidate with potential use in Graves' disease and TED; preclinical.

VRDN-006 / VRDN-008

Preclinical · Active

Target FcRn

Partnerships Paragon Therapeutics: option/research agreement covering antibody technology

Status note Portfolio of engineered anti-neonatal FcRn inhibitors in preclinical development; filing names no indications.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	VRDN-003
Lead indication	Thyroid Eye Disease
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06625411	Phase 3	Active, not recruiting	Sponsor	VRDN	—	Thyroid Eye Disease	—
NCT06625398	Phase 3	Active, not recruiting	Sponsor	VRDN	—	Thyroid Eye Disease	—
NCT06812325	Phase 3	Active, not recruiting	Sponsor	VRDN	—	Thyroid Eye Disease (TED)	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Viridian Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	2,383,025	+411,347	0.22%	2026-08-14
OrbiMed Advisors	1,000,000	+1,000,000	0.02%	2026-08-14
Ikarian Capital	425,000	+425,000	1.28%	2026-08-14
ADAR1 Capital Management	0	-304,422	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

VRDN — Viridian Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials

Institutional holders